New York, Jan 23, 2026, 12:53 ET — Regular session underway.
- Shares of Thermo Fisher dropped roughly 2% by midday, underperforming the wider market
- After hitting a record high, the stock pulled back as traders turned their focus to earnings due next week
- Shares in life-science tools peers dipped as well
Shares of Thermo Fisher Scientific dropped close to 2% on Friday, surrendering earlier gains after the stock briefly surged toward $640 during the session.
The pullback is significant since Thermo Fisher stands as a key bellwether for the sector. Investors are bracing for next week’s results, which might shift expectations for demand in lab equipment and bioproduction services.
The broader tape showed a mixed picture. The S&P 500 tracker SPY held steady, but the health-care sector ETF XLV dipped.
Thermo Fisher slipped, dragging down other life-science tools stocks like Danaher, Agilent, and Illumina.
Thermo Fisher’s shares slid on Friday after a strong rally earlier in the week. On Wednesday, the stock climbed 2.8% to settle at $636.30, hitting a new 52-week high and outpacing the broader market, according to MarketWatch data. 1
Next week’s earnings present the first big calendar event. Thermo Fisher plans to release its fourth-quarter and full-year 2025 results before the market opens on Thursday, Jan. 29. The company will follow up with a conference call at 8:30 a.m. ET. 2
At an investor conference earlier this month, CEO Marc Casper reminded investors about that date, saying the company plans to “report our results and give our guidance” at the end of the month. 3
Several analysts are forecasting a strong quarter, with MarketBeat projecting earnings per share of $6.44 on roughly $12.0 billion in revenue. 4
A separate filing this week clarified routine balance-sheet housekeeping: a Form 25 notice flagged the delisting of Thermo Fisher’s 1.400% senior notes due 2026, not its common shares. 5
There’s a risk that next week’s outlook could fall short after the stock hit record highs, particularly if management takes a cautious stance on customer spending heading into 2026.
Traders are focused on Thursday’s release, seeking updated guidance and any insights into order patterns and demand from pharma, biotech, and research sectors. 2
